You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The pilot program is intended to increase consistency and predictability when determining conformity with consensus standards and test methods.
Last week, readers were most interested in NIH's RADx-UP program to address disparities in COVID-19 testing in underserved communities.
The company is planning to fund projects for SARS-CoV-2 testing, early disease detection, disease prognostics, and public health genomics projects.
Lucira Health's at-home molecular test received Emergency Use Authorization in November for prescription use.
DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years.
The technology underlying the test was developed by Dutch firm Minicare, which was acquired by Siemens in 2019.
The companies began working together in 2018, when MEDx was known as Qiagen Translational Medicine, on companion and in vitro diagnostics.
Novacyt noted that it generated $98.5 million in the first quarter of 2021, about half of which came from sales to the DHSC.
News items for the in vitro diagnostics industry for the week of April 5, 2021.
The three tests run on the firm's Vidas systems and expand the firm's footprint in vector-borne disease.
Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.
CA Healthcare Acquisition, a special purpose acquisition company, said the transaction will support the development of LumiraDx’s pipeline of more than 30 assays.
The immunoassay can be used to monitor cancer cell remnants in a patient's body and help determine which patients need less invasive treatment.
The Israeli-based startup will use the funds to continue development of its EpiCheck methylation platform and to develop the Lung EpiCheck assay.
The company's test uses self-collected saliva samples from potential parents to assess their future child's genetic predisposition to various diseases.
The prescription-only test from Symbiotica is designed to detect immunoglobulin G against SARS-CoV-2 in dried blood spots obtained via fingerstick.
MyHealthChecked's kit uses Yourgene Health's Clarigene SARS-CoV-2 PCR test and EKF Diagnostics' PrimeStore MTM sample collection device.
The firm, a University of Edinburgh spinout, will use the funding to in-license its BioCollector liquid biopsy platform and launch initial trials.
The contracts are for two lateral flow rapid antigen tests, a laboratory-based test to detect and identify SARS-CoV-2 variants, and a rapid RT-PCR test.
The test measures the level of antibodies to the spike protein of the virus and can be used to establish immunity and vaccine efficacy.
Novel Microdevices is developing a portable, sample-to-answer instrument that is designed to perform molecular testing on untreated patient samples.
Avacta said that the deal will enable scientists to perform a laboratory test to detect the SARS-CoV-2 spike protein and some of its dominant variants.
For the three months ended March 31, the firm said that preliminary revenues for Q1 are expected to be $1.4 million compared with $3.2 million a year ago.
The firm said it has licensed an instrument-free rapid immunoassay from an undisclosed test manufacturer that has received FDA Emergency Use Authorization.
Invitae expects that Genosity's software and data management platform will allow it to quickly advance several oncology tests in development.